US Pharma MarketingThe post MAIA activates new site for THIO-101 Phase II trial appeared first on Clinical Trials Arena.
MAIA activates new site for THIO-101 Phase II trial
MAIA Biotechnology has activated new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for the Phase II THIO-101 expansion trial evaluating its telomere-targeting agent, ateganosine, as a third-line therapy for NSCLC. The trial is studying ateganosine followed by cemiplimab in NSCLC patients resistant to checkpoint inhibitors and chemotherapy. The study is assessing ateganosine’s safety, tolerability, and efficacy, using overall response rate as the primary endpoint. Credit: PaeGAG / Shutterstock.com. MAIA Biotechnology has activated a new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for the Phase II THIO-101 expansion trial.…
MAIA Biotechnology has activated new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for the Phase II THIO-101 expansion trial evaluating its telomere-targeting agent, ateganosine, as a third-line therapy for NSCLC.
Source: Clinical Trials Arena